1. Home
  2. WKC vs NTLA Comparison

WKC vs NTLA Comparison

Compare WKC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WKC
  • NTLA
  • Stock Information
  • Founded
  • WKC 1984
  • NTLA 2014
  • Country
  • WKC United States
  • NTLA United States
  • Employees
  • WKC N/A
  • NTLA N/A
  • Industry
  • WKC Oil Refining/Marketing
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • WKC Energy
  • NTLA Health Care
  • Exchange
  • WKC Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • WKC 1.4B
  • NTLA 1.2B
  • IPO Year
  • WKC N/A
  • NTLA 2016
  • Fundamental
  • Price
  • WKC $25.98
  • NTLA $12.52
  • Analyst Decision
  • WKC Hold
  • NTLA Buy
  • Analyst Count
  • WKC 4
  • NTLA 20
  • Target Price
  • WKC $28.75
  • NTLA $25.48
  • AVG Volume (30 Days)
  • WKC 551.2K
  • NTLA 10.8M
  • Earning Date
  • WKC 10-23-2025
  • NTLA 11-06-2025
  • Dividend Yield
  • WKC 3.09%
  • NTLA N/A
  • EPS Growth
  • WKC N/A
  • NTLA N/A
  • EPS
  • WKC N/A
  • NTLA N/A
  • Revenue
  • WKC $37,648,100,000.00
  • NTLA $52,857,000.00
  • Revenue This Year
  • WKC N/A
  • NTLA $9.20
  • Revenue Next Year
  • WKC $2.16
  • NTLA N/A
  • P/E Ratio
  • WKC N/A
  • NTLA N/A
  • Revenue Growth
  • WKC N/A
  • NTLA 14.99
  • 52 Week Low
  • WKC $22.71
  • NTLA $5.90
  • 52 Week High
  • WKC $31.54
  • NTLA $28.25
  • Technical
  • Relative Strength Index (RSI)
  • WKC 52.50
  • NTLA 34.40
  • Support Level
  • WKC $25.55
  • NTLA $11.63
  • Resistance Level
  • WKC $26.19
  • NTLA $13.60
  • Average True Range (ATR)
  • WKC 0.56
  • NTLA 1.54
  • MACD
  • WKC 0.06
  • NTLA -1.52
  • Stochastic Oscillator
  • WKC 59.06
  • NTLA 5.38

About WKC World Kinect Corporation

World Kinect Corp is an energy management company involved in providing supply fulfillment, energy procurement advisory services, and transaction and payment management solutions to commercial and industrial customers. It sells and delivers liquid fuels, natural gas, electricity, renewable energy, and other sustainability solutions. The company operates in three reportable segments consisting of aviation, land, and marine. The company earns the majority of its revenue from the Aviation segment.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: